Obesity – Page 11

Novo Nordisk’s CagriSema Falls Short of Weight Loss Expectations, Highlighting High Investor Expectations

10 months ago talkbio0Tagged CagriSema, Expectations, investor, Nordisk, Obesity, REDEFINE 1 trial, Weight-Loss Agents

CagriSema, Novo Nordisk, Weight Loss Drugs, REDEFINE 1 Trial, Obesity Treatment, Investor Expectations

CagriSema Achieves 22.7% Weight Loss in Phase 3 REDEFINE 1 Trial, Falling Short of 25% Target

10 months ago talkbio0Tagged cagrilintide, CagriSema, Nordisk, Obesity, Phase 3 REDEFINE 1 Trial, semaglutide, Weight Loss

CagriSema, Weight Loss, Phase 3 REDEFINE 1 Trial, Obesity Treatment, Novo Nordisk, Semaglutide, Cagrilintide

Rhythm Pharmaceuticals Secures Expanded FDA Approval for IMCIVREE to Treat Genetic Obesity in Children as Young as 2 Years Old

10 months ago talkbio0Tagged Approved, Bardet-Biedl Syndrome, Genetic obesity, Imcivree, leptin receptor, human, Obesity, PCSK1 gene, Pediatric brand name, POMC, Rhythm, setmelanotide, United States Food and Drug Administration

Rhythm Pharmaceuticals, IMCIVREE, setmelanotide, FDA approval, genetic obesity, Bardet-Biedl syndrome, POMC, PCSK1, LEPR deficiency, pediatric obesity treatment

Novo Nordisk’s Vision for the Future of GLP-1 Therapies: Expanding Beyond Diabetes and Obesity

10 months ago talkbio0Tagged advancements, agonists, Chronic disease, Diabetes Mellitus, Non-Insulin-Dependent, Future, Glucagon-Like Peptide 1, Nordisk, Obesity, semaglutide

GLP-1 agonists, Novo Nordisk, Type 2 diabetes, Obesity, Future treatments, Chronic diseases, Semaglutide, Tirzepatide, Therapeutic advancements

Merck & Co. Enters Oral GLP-1 Market with $2 Billion Hansoh Pharma Deal

10 months ago talkbio0Tagged GLP-1 receptor, Hansoh Pharma, Merck & Co., Obesity, Oral cavity, Partnership, pharmaceutical collaboration

Merck & Co., Hansoh Pharma, GLP-1 receptor agonist, oral obesity treatment, pharmaceutical collaboration, biotech partnership

Merck Enters Obesity Market with $2 Billion Deal for Chinese Oral GLP-1 Drug

10 months ago talkbio0Tagged Benefit, cardiometabolic, Glucagon-Like Peptide 1, Hansoh Pharma, HS-10535, Merck, Obesity, Oral cavity, Weight Loss

Merck, Obesity, Oral GLP-1, Hansoh Pharma, HS-10535, Weight Loss, Cardiometabolic Benefits

EU Regulator Determines Mounjaro Effective for Sleep Apnea, No Separate Approval Required

10 months ago talkbio0Tagged EU, European Medicines Agency, Mounjaro, Obesity, Regulators (device)

Mounjaro, sleep apnea, EU regulator, European Medicines Agency (EMA), tirzepatide, weight loss, obesity

Eli Lilly and Ro Partner to Expand Access to Affordable Zepbound Single-Dose Vials for Obesity Treatment

10 months ago talkbio0Tagged Affordable medication, CALR gene, Eli, Eli Lilly, Obesity, Pharmaceutical Services, Self-pay, single-dose, Telemedicine, Zepbound

Eli Lilly, Ro, Zepbound, Single-dose vials, Obesity treatment, Telehealth, Affordable medication, Self-pay pharmacy

BioAge Labs Halts Phase 2 Obesity Trial Due to Liver Safety Concerns Just Two Months After IPO

11 months ago talkbio0Tagged Azelaprag, BioAge Labs, concerns, Eli, Eli Lilly, IPO, liver safety, Obesity, Phase 2 trial

BioAge Labs, Phase 2 trial, obesity, liver safety concerns, azelaprag, Eli Lilly, tirzepatide, IPO

BioAge Labs Discontinues Phase II Obesity Study Due to Safety Concerns, Stock Plummets

11 months ago talkbio0Tagged Azelaprag, BioAge Labs, concerns, crash, liver transaminitis, Obesity, Phase 2 Clinical Trials, Safety

BioAge Labs, azelaprag, obesity treatment, Phase II study, safety concerns, liver transaminitis, stock crash